Member of the Strategic Project Committee (CSP) of the Eurobiomed Competitiveness Cluster since 2013.
In 1998 he obtained his diploma as a Doctor (Clinical Hematology) at the Faculty of Medicine Saint-Antoine, Paris VI. In 2001 he completed a Doctorate in “Chemical and Biological Sciences for Health” at Montpellier I University.
In university and hospital activities, he has focused on developing cell therapy and knowledge around stem cells at the national and international level. Cell therapy makes it possible to treat pathologies that are beyond the use of drugs and surgery by injecting “drug” cells. It is at the heart of a young branch of medicine, regenerative medicine. Associated with gene therapy, it makes it possible to consider the correction of a certain number of genetic pathologies. His teaching is aimed at students from the first year of medicine (PACES) to doctors in the context of post-graduate education, including numerous master's degrees. He is responsible for the University Diploma in Regenerative Medicine (UM), and several teaching units. In addition, he has a strong supervisory activity: UTC interns and students from the research team.
Since 2009, he has been responsible for the Cellular Therapy Unit (UTC) at Montpellier University Hospital. Since 2014 he has also been coordinator of the Cellular and Tissue Engineering Department of the University Hospital, and Director of the Placental Blood Bank. He created the “pluripotent stem cells” theme within the IRMB and published the first work of a French team on human embryonic stem cells in 2007 (Stem Cells, Assou et al.).
The two axes of his current research activities are the analysis of the genetic integrity of pluripotent stem cells during their in vitro culture or after reprogramming, and their differentiation into bronchial epithelium, a collaborative work with Professor Arnaud's team Bourdin from the Department of Pneumology at Montpellier University Hospital.
His research work has resulted in a total of 113 publications in international peer-reviewed journals, totaling a Hirsh Factor of 51.
John De Vos is co-founder of the start-up Stem Genomics (iLab Prize 2018, iNov Prize 2019) and co-founder of the learned society French Society for Stem Cell Research (FSSCR) in 2017, which he has chaired since 2021. He is also President of the College of Histologists, Embryologists and Cytogeneticists (CHEC).
Member of the Board of the French Society for Cellular and Gene Therapy (SFTCG) and of the Board of Directors and secretary of the College of Histologists, Embryologists and Cytogeneticists (CHEC) since 2016
Member of the Board of Directors of the French Society of Marrow Transplantation and Cellular Therapy (SFGM-TC) – 2012-2018
